All In Biotech

Drug Trial Radar · NCT06908642

Evaluation the Safety of hemay005 Tablets

Evaluation of the Safety of Hemay005 Tablets in Multiple Doses and Different Administration Methods in Multiple Administrations for Chinese Adult Healthy Subjects in a Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

468

Actual

Start

Dec 25, 2024

Primary completion

Jun 3, 2025

Study completion Jun 3, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Hemay005 tabletDrug

    Hemay005 is a small molecule PDE4 inhibitor.

  • PlaceboDrug

    Placebos are the same as drugs, but contain no Hemay005.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.Time frame: 14 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.